Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)
Launched by PHARMANEUROBOOST N.V. · May 5, 2008
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female patients
- • 18-65 years inclusive
- • Suffering from a moderate to severe MDD as defined by DSM IV with an existence of depressed mood and loss of interest/anhedonia for at least four weeks and no longer than six months for the current episode
- • Diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI) version 5.0.0.
- • Clinical global impression - severity scale (CGI-S) rating of at least four and a minimum Hamilton Depression Scale (HAM-D) 17 items total score of 18 at screen and baseline
- • A non-psychotic state
- • Where appropriate, male patients should agree to use barrier contraceptive measures (condoms) during the course of the study and for three months after the last dose of medication
- Exclusion Criteria:
- • Premenopausal females not using adequate contraceptive measures
- • Considered by the investigator to be a significant risk of suicide or scoring 5 or more on the MADRS question 10
- • Significant other psychiatric illness which would interfere with trial assessments - co-morbid generalised anxiety disorder (GAD) and panic disorder will be permitted where MDD is considered the primary diagnosis
- • Significant physical illness which would interfere with trial assessments
- • Reduced hepatic function
- • Epilepsy
- • History of cardiac dysrhythmia
- • Alcohol intake above accepted UK ranges
- • Recent (1 week) antidepressant (except for fluoxetine - 4 weeks and St John's Wort or MAOI's - 14 days), benzodiazepine or any other psychotropic medication ingestion including lithium or other mood stabilisers
- • Resistant depression defined as having failed to respond to
- • Two previous antidepressants at an adequate dose ingested for at least 4 weeks during the current episode
- • To an augmentation therapy with an atypical antipsychotic drug
- • Electroconvulsive therapy (ECT) for the current episode
- • Formal psychotherapy or alternative treatments for one week prior to or during the study
About Pharmaneuroboost N.V.
Pharmaneuroboost N.V. is an innovative biopharmaceutical company dedicated to advancing neurological health through the development of cutting-edge therapies. With a strong emphasis on research and clinical trials, Pharmaneuroboost focuses on addressing unmet medical needs in the field of neurodegenerative disorders and cognitive enhancement. The company leverages a multidisciplinary approach, combining expertise in neuroscience, pharmacology, and clinical development to bring novel treatments to market. Committed to improving patient outcomes, Pharmaneuroboost strives to foster partnerships with academic institutions and industry leaders to accelerate the translation of scientific discoveries into effective therapeutic solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Glasgow, Scotland, United Kingdom
Patients applied
Trial Officials
Erik Buntinx, MD
Study Chair
PharmaNeuroBoost N.V.
Alan Wade, MG
Study Director
CPSResearch
Gordon Crawford, MD
Principal Investigator
CPSResearch
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials